Neurogenesis as a potential therapeutic strategy for neurodegenerative disorders.
Kelleher-Andersson
J
J
Neuronascent, Inc., Clarksville, MD, USA. judykelleher@comcast.net
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D019208:Brain-Derived Neurotrophic Factor / Q000187:drug effects; D050882:CREB-Binding Protein; D049109:Cell Proliferation / Q000187:drug effects*; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology; D004032:Diet; D005247:Feeding Behavior / Q000502:physiology; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D009474:Neurons / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D009569:Nitric Oxide / Q000494:pharmacology* / Q000627:therapeutic use*; D009603:Nitroso Compounds / Q000494:pharmacology / Q000627:therapeutic use; D009687:Nuclear Proteins / Q000187:drug effects; D051381:Rats; D015534:Trans-Activators / Q000187:drug effects
D000928:Antidepressive Agents; D019208:Brain-Derived Neurotrophic Factor; D018696:Neuroprotective Agents; D009603:Nitroso Compounds; D009687:Nuclear Proteins; D015534:Trans-Activators; C094210:2,2'-(hydroxynitrosohydrazono)bis-ethanamine; D009569:Nitric Oxide; D050882:CREB-Binding Protein; C494365:Crebbp protein, rat